The Trump MFN EO: Terrible as a Policy Prescription … but Solid as a PR Stunt
Shares:
If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
As is tradition, Merck is out as the first company to talk about 2023 list- and net-price changes across its portfolio. The company dropped its annual Pricing Action Transparency Report
In some ways, I’ve given up on my dream that stories about beginning-of-the-year price changes for prescription drugs will be thoughtful. Yes, it would be nice if the stories were